Adverse Reactions Events Immunization 
The Checkup by Singlecare
DECEMBER 29, 2022
The first step in identifying or managing a medication reaction is knowing what you’re dealing with. Drug reactions may be immunologic or non-immunologic. Meaning, they may be caused by the immune system or other factors. . Immunologic reactions. Nonimmunologic reactions. Most common culprits of reactions.
European Pharmaceutical Review
DECEMBER 19, 2022
The failure to achieve a complete response (CR), or the disappearance of all signs of cancer as seen on cystoscopy, biopsied tissue, and urine, is associated with an increased risk of death or a disease-worsening event. Without treatment, the cancer can invade, damage tissues and organs, and spread through the body.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
NOVEMBER 24, 2022
Immune-mediated adverse reactions (ARs) occurred in 21 percent of patients treated with Libtayo ® and led to permanent discontinuation in 4.6 The most common immune-mediated ARs were hypothyroidism (6.8 percent), hyperthyroidism (3 percent), immune-mediated pneumonitis (2.6 percent), immune-mediated hepatitis (2.4
Pharmaceutical Technology
NOVEMBER 20, 2022
According to data from Phase III trials, the booster dose elicited greater immune responses to levels in line with or over those linked to protection against Covid-19. Additionally, data from these trials showed that local and systemic reactions following the booster dosing lasted for a median duration of nearly two days.
pharmaphorum
NOVEMBER 4, 2020
Grade 3–4 adverse events occurred in 57% of people receiving Tecentriq and Avastin and 55% of people receiving sorafenib. The most frequent serious adverse reactions for the combination, occurring in 2% or more of patients, were bleeding in the gastrointestinal tract and fever.
Hospital Pharmacy Europe
OCTOBER 23, 2023
It is designed to simultaneously bind to both the cluster of differentiation (CD)3 proteins on immune T cells and the CD20 proteins on cancerous B cells and activate the T cell to destroy the B cell. Four patients (2.4%) experienced a fatal adverse reaction – ICANS in one patient (0.6%) and pneumonia in three patients (1.8%).
pharmaphorum
JANUARY 26, 2022
The regulatory move applies only to trials of magrolimab given alongside Bristol-Myers Squibb’s Vidaza (azacitidine), and stems from an “imbalance” in investigator-reported serious adverse events between study arms, said the drugmaker.
Expert insights. Personalized for you.
98 
Let's personalize your content